Soleno Therapeutics has addressed a report in the FDA’s Adverse Event Reporting System concerning the death of a 17-year-old patient, which was determined not to be related to their treatment with VYKAT XR. The company emphasizes that VYKAT XR has a proven safety profile and that adverse events will be reported in compliance with legal requirements, while highlighting the complexities of Prader Willi Syndrome, which can lead to various health complications.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.